Consensus NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
3.8 ^USD	+0.53%		+17.65%	+2.80%

Apr. 17	Sector Update: Health Care Stocks Mixed Wednesday Afternoon	MT
Apr. 17	NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise	MT

Evolution of the average Target Price on NeuroBo Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fa93303425a926b5cb8a6e82e504677f.X1uMLjVDxJcDDpHOW7vS42fjsCnLyfc8lleo5J_b-Oo.ZzfFf0MEqqRySf6rNfiDzgGC3UipvK1QonrNsu_2qKNyDblbUnaQ_2xjyA~ece593000929998dcacc7e8510f7d26e

Analyst Recommendations on NeuroBo Pharmaceuticals, Inc.

Ladenburn Thalmann Starts NeuroBo Pharmaceuticals at Buy With $6 Price Target	22-12-07	MT
NEUROBO PHARMACEUTICALS : HC Wainwright Adjusts Price Target on NeuroBo Pharmaceuticals to $16 From $20, Reiterates Buy Rating	21-02-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.8 USD

Average target price

36.5 USD

Spread / Average Target

+860.53%

High Price Target

48 USD

Spread / Highest target

+1,163.16%

Low Price Target

25 USD

Spread / Lowest Target

+557.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NeuroBo Pharmaceuticals, Inc.

Ladenburg Thalmann
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar